ADC Linker

Aminoxyacetamide-PEG3-azide is a non-cleavable linker designed for antibody-drug conjugate (ADC) synthesis, targeting efficient conjugation in bioconjugation applications. This reagent features an azide group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) and is also suitable for strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups. Its versatile click chemistry capabilities make it an essential tool in the development of targeted therapeutics.

DBCO-PEG3-TCO is a non-cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs), featuring a 3-unit polyethylene glycol (PEG) spacer. This reagent facilitates click chemistry through its dibenzocyclooctyne (DBCO) moiety, enabling strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-functionalized compounds. Additionally, the TCO group supports inverse electron demand Diels-Alder (iEDDA) reactions with tetrazine-containing molecules, making DBCO-PEG3-TCO a versatile tool for advancing ADC development in therapeutic research.

m-PEG11-Amine is a cleavable linker designed for the functionalization of antibody-drug conjugates (ADCs). This polyethylene glycol (PEG)-based compound enhances solubility and stability of ADCs, facilitating targeted delivery of cytotoxic agents. In addition to its application in ADCs, m-PEG11-Amine is also suitable for the synthesis of PROTACs (Proteolysis Targeting Chimeras), enabling targeted protein degradation research.

(2R,4R)-1-tert-Butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate functions as a non-cleavable linker for antibody-drug conjugates (ADCs), facilitating the formation of stable conjugates for targeted cancer therapies. This compound serves as an effective alkyl chain-based PROTAC linker, allowing for the development of proteolysis-targeting chimeras that can induce selective degradation of specific proteins in research studies. Its robust mechanism makes it a valuable tool in the fields of drug development and targeted therapy.

Mal-PEG2-Val-Cit-PAB-OH is a cleavable linker specifically designed for use in antibody-drug conjugates (ADCs). This compound enables controlled release of therapeutic agents, enhancing the efficacy and safety of ADC formulations. Additionally, it serves as a versatile PROTAC linker, facilitating the synthesis of proteolysis-targeting chimeras for targeted protein degradation research.

4-Methyl-4-(methyldisulfanyl)pentanoic acid is a cleavable linker utilized in the synthesis of antibody-drug conjugates (ADCs). Its unique disulfide bond enables selective release of therapeutic agents upon internalization by target cells, enhancing the efficacy of ADCs in cancer therapy. This compound is crucial for researchers developing novel ADC formulations aimed at improving targeted delivery and reducing systemic side effects.

DBCO-NHCO-PEG4-NH-Boc is a versatile PROTAC linker featuring a cleavable structure designed for the synthesis of PROTACs and antibody-drug conjugates (ADCs). This compound utilizes a DBCO moiety, enabling efficient strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. Its PEG4 spacer enhances solubility and stability, making it suitable for various biological applications in drug development and therapeutic research.

SMPT is a non-cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). It facilitates stable attachment between antibodies and cytotoxic drugs, ensuring targeted delivery without premature release. This linker is essential for enhancing the therapeutic efficacy of ADCs in cancer research and development.

Methyl 1-Cbz-azetidine-3-carboxylate is a non-cleavable linker utilized in the development of antibody-drug conjugates (ADCs). This compound can also serve as an alkyl chain-based PROTAC linker, facilitating the synthesis of PROTACs for targeted protein degradation studies. Its unique structure provides robust stability and effective conjugation capabilities, making it an essential reagent for advanced therapeutic research and development.

m-PEG6-CH2CH2CHO is a PEG-based non-cleavable linker employed in the development of antibody-drug conjugates (ADCs). This compound facilitates stable conjugation between antibodies and therapeutic agents, ensuring effective targeting and delivery of antivirals or chemotherapeutics. Additionally, m-PEG6-CH2CH2CHO can also serve as a linker in the synthesis of PROTACs, contributing to targeted protein degradation research applications.

Azidoethyl-SS-ethylamine is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound features an azide functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions with alkyne-containing molecules. Additionally, Azidoethyl-SS-ethylamine is capable of undergoing strain-promoted alkyne-azide cycloaddition (SPAAC) with DBCO or BCN groups, making it a versatile tool for bioconjugation applications in chemical biology and pharmacology research.

DBCO-NHCO-PEG4-amine is a PEG-based linker designed for use in antibody-drug conjugates (ADCs) and PROTACs. This cleavable linker facilitates the conjugation of payloads such as MMAE to antibodies, enhancing targeted delivery to cancer cells. It has demonstrated compelling biological activities, with EC50 values of 280 nM and 22 nM for DBCO-VCpAB MMAE and DBCO-TRX MMAE, respectively, in SKBR3 cells, making it a valuable tool for researchers investigating targeted therapies.

Mc-d-Val-d-Cit-PAB-PNP is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the targeted delivery of cytotoxic agents to specific cells, enhancing therapeutic efficacy while minimizing systemic toxicity. It is particularly valuable in studies focused on ADC development and optimization in cancer research.

MCC is a non-cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). By forming stable covalent bonds between antibodies and cytotoxic drugs, MCC enhances the therapeutic efficacy of ADCs. This compound is widely utilized in research aimed at developing targeted cancer therapies, ensuring localized delivery of potent agents while minimizing systemic toxicity.

NHPI-PEG2-C2-NHS ester is a non-cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This 2-unit PEG linker provides increased stability and solubility, facilitating the delivery of cytotoxic agents to targeted cells. Its application in ADC development enhances therapeutic efficacy and minimizes off-target effects, making it a valuable reagent for cancer research and drug formulation studies.

Ac-EEVC-OH is a linker designed for antibody-drug conjugate (ADC) synthesis. This compound facilitates the conjugation of cytotoxic agents to antibodies, enhancing targeted delivery and efficacy in cancer therapy. Its application in ADC development supports research aimed at improving therapeutic outcomes and minimizing off-target effects.

Mal-amide-PEG4-Val-Cit-PAB-OH is a cleavable linker featuring a Maleimide group, primarily used in the synthesis of antibody-drug conjugates (ADCs). This linker facilitates the conjugation of therapeutic agents to antibodies, ensuring targeted delivery in cancer research and therapeutic applications. Its design allows for precise cleavage in the tumor environment, enhancing the efficacy and reducing off-target effects of ADCs.

Tr-PEG3-OH is a non-cleavable linker comprised of a three-unit polyethylene glycol (PEG) chain, designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound enhances the solubility and stability of ADCs, facilitating targeted delivery of cytotoxic agents to specific cells. Its applications extend to PROTAC (proteolysis-targeting chimera) technology, enabling the development of innovative therapies that harness targeted protein degradation.

Propargyl-PEG7-acid is a PEG-based linker designed for use in antibody-drug conjugates (ADCs) and proteolysis-targeting chimeras (PROTACs). It features a propargylic group that facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc), enabling effective conjugation to azide-containing molecules. This compound serves as a cleavable linker, providing versatility in drug delivery systems and targeted therapy research. Propargyl-PEG7-acid is essential for studies focusing on the development of innovative therapeutic modalities through advanced chemical synthesis techniques.

(2R,4S)-1-(tert-Butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid acts as a non-cleavable linker for antibody-drug conjugates (ADCs). This compound facilitates the stable attachment of therapeutic agents to antibodies, enhancing targeted delivery in cancer research. Additionally, it serves as an alkyl chain-based linker in the development of PROTACs, supporting studies in targeted protein degradation.

Mal-PEG4-PFP ester is a non-cleavable ADC linker featuring a maleimide moiety, a polyethylene glycol (PEG) chain of four units, and a PFP ester. This linker facilitates the stable conjugation of antibody-drug pairs, enhancing the efficacy and specificity of targeted therapies. It is especially useful in the development of antibody-drug conjugates (ADCs) for cancer treatment and other therapeutic applications, allowing for improved delivery of cytotoxic agents to tumor cells.

N-Boc-4-hydroxy-L-proline methyl ester serves as a non-cleavable linker for antibody-drug conjugates (ADCs), facilitating the targeted delivery of therapeutic agents. This compound also functions as an alkyl chain-based linker in the synthesis of PROTACs (proteolysis-targeting chimeras), contributing to the modulation of protein degradation pathways. Its utility in both ADC and PROTAC applications makes it valuable for advancing research in targeted therapies and protein regulation.

Hydroxy-PEG2-(CH2)2-Boc is an uncleavable linker specifically designed for use in antibody-drug conjugates (ADCs). This compound facilitates the stable attachment of therapeutic agents to antibodies, enhancing delivery and efficacy in targeted cancer therapies. Additionally, Hydroxy-PEG2-(CH2)2-Boc serves as a suitable linker for the synthesis of PROTACs, aiding in the development of targeted protein degradation applications.

SC209 intermediate-1 is an advanced antibody-drug conjugate (ADC) linker designed to facilitate the synthesis of ADCs. Its efficient coupling properties enable the attachment of cytotoxic agents to antibodies, enhancing targeted delivery for cancer therapy. This compound is essential for researchers developing novel ADC formulations aimed at improving therapeutic efficacy and minimizing off-target effects.

BCN-exo-PEG3-maleimide is an ADC linker featuring three PEG units and a bidentate macrocyclic ligand, BCN. It facilitates the formation of stable triazole structures through click chemistry with azide-containing molecules, eliminating the need for catalysts. The maleimide moiety is designed to degrade in aqueous conditions, making it suitable for various drug delivery applications and enhancing the efficacy of antibody-drug conjugates (ADCs) in targeted therapy research.

Allyl (2-aminoethyl)carbamate hydrochloride serves as a cleavable linker in antibody-drug conjugates (ADCs). It facilitates the release of therapeutic agents in targeted cancer therapies, enhancing the specificity and efficacy of treatment. This compound is valuable for research applications focusing on ADC development and optimization.

Cyclooctyne-O-PFP ester is a cleavable linker designed for use in antibody-drug conjugates (ADCs). This reagent features an alkyne functional group, facilitating copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions with azide-containing molecules. Its efficient coupling and release properties enhance the development of targeted therapeutics in medicinal chemistry and drug delivery applications.

Allyl (2-aminoethyl)carbamate is a cleavable linker designed for use in antibody-drug conjugate (ADC) development. This compound facilitates the attachment of cytotoxic agents to targeting antibodies, enabling selective delivery to cancer cells. Its stability under physiological conditions and subsequent release mechanism make it a valuable tool in enhancing the therapeutic efficacy of ADCs in cancer research.

Azido-PEG4-Val-Cit-PAB-OH is a cleavable polyethylene glycol (PEG) linker designed for use in antibody-drug conjugates (ADCs) and proteolysis-targeting chimeras (PROTACs). This compound features an azide group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules, as well as strain-promoted alkyne-azide cycloaddition (SPAAC) with DBCO or BCN moieties. Its versatility as a click chemistry reagent supports diverse applications in chemical biology and drug development.

m-PEG11-acid is a non-cleavable linker composed of 11 ethylene glycol units, functioning as a versatile agent in the synthesis of antibody-drug conjugates (ADCs) and PROTACs. This polyethylene glycol (PEG)-based linker enhances the solubility and pharmacokinetics of the conjugates while facilitating targeted degradation of proteins in research applications. m-PEG11-acid is crucial for investigating the mechanisms of protein regulation and therapeutic strategies in drug discovery.

PDP-Pfp is a reducible ADC linker designed to enable targeted delivery of antibody-drug conjugates (ADCs) to the extracellular loop 1 (ECL1) of TM4SF1 (transmembrane 4 L6 family member 1). This linker facilitates effective payload release in the tumor microenvironment, enhancing the therapeutic potential of ADCs. It is suitable for applications in cancer research and the development of innovative therapeutics targeting TM4SF1-related pathways.

D-Proline, 4-hydroxy-, methyl ester hydrochloride is a non-cleavable linker specifically designed for antibody-drug conjugates (ADCs). This compound serves as a key component in the synthesis of ADCs, facilitating the stable attachment of therapeutic agents to antibodies. Additionally, it functions as an alkyl chain-based PROTAC linker, enabling the development of proteolysis-targeting chimeras for targeted protein degradation research.

vc-PABC-DM1 is an antibody-drug conjugate (ADC) linker that incorporates a disulfide bond to facilitate controlled drug release. This compound is instrumental in synthesizing ADCs, allowing for targeted delivery of toxins to cancer cells. Additionally, vc-PABC-DM1 can be utilized in studies assessing serum stability, contributing to the understanding of ADC pharmacokinetics and therapeutic efficacy.

SPDMB is a glutathione-cleavable linker designed for antibody-drug conjugates (ADCs). This compound enables the selective release of cytotoxic agents within target cells, enhancing therapeutic efficacy while minimizing systemic toxicity. SPDMB is crucial for constructing ADCs in research applications focused on targeted cancer therapies and drug delivery mechanisms.

bis-PEG2-endo-BCN is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound features a cyclooctyne (BCN) moiety that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, enabling precise conjugation. Its implementation in ADC development enhances targeted delivery of therapeutics, making it valuable for research applications in oncology and drug development.

Azidoethyl-SS-ethylazide is a cleavable linker specifically designed for antibody-drug conjugate (ADC) synthesis. This compound features an azide moiety allowing it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-functionalized molecules. Additionally, Azidoethyl-SS-ethylazide can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with entities containing dibenzocyclooctyne (DBCO) or bicyclo[6.1.0]non-4-yne (BCN) groups, facilitating efficient conjugation in chemical biology applications.

Sulfo-SNPB is a cleavable linker designed for use in antibody-drug conjugates (ADCs). It facilitates the conjugation of antibodies to therapeutic agents, allowing for targeted delivery and enhanced efficacy in cancer treatment. This linker is ideal for research applications focused on developing innovative ADC formulations and optimizing drug delivery systems.

Mal-Ph-CONH-PEG4-NHS ester is a non-cleavable linker designed for use in antibody-drug conjugates (ADCs). This 4-unit polyethylene glycol (PEG) linker facilitates the stable attachment of cytotoxic agents to antibodies, enhancing the efficacy and specificity of targeted therapies. It is suitable for research applications aimed at developing advanced ADC formulations for cancer treatment.

Folate-PEG3-amine is a cleavable 3-unit polyethylene glycol (PEG) linker designed for the synthesis of antibody-drug conjugates (ADCs). The folate moiety facilitates targeted delivery to folate receptor-expressing cells, enhancing therapeutic efficacy while minimizing off-target effects. This reagent is ideal for research applications focused on the development and optimization of ADCs for cancer treatment.

Ald-Ph-amido-PEG2-C2-NHS ester is a non-cleavable linker designed for antibody-drug conjugation (ADC) applications. This 2-unit PEG linker facilitates stable attachment between antibodies and various cytotoxic agents, enhancing the therapeutic potential of ADCs. Its robust structure promotes efficient delivery and release of therapeutic agents, making it suitable for cancer research and targeted therapy development.

Hydroxy-PEG1-acid is a non-cleavable polyethylene glycol (PEG) linker designed for use in antibody-drug conjugates (ADCs). This reagent facilitates the conjugation of therapeutic antibodies to cytotoxic drugs, enhancing their efficacy and selectivity against target cells. Its properties make it an ideal choice for optimizing ADC formulation and improving pharmacokinetics in cancer therapeutics and other targeted therapies.

m-PEG4-MS is a polyethylene glycol (PEG)-based linker designed for use in the synthesis of PROTACs and antibody-drug conjugates (ADCs). This cleavable linker facilitates the precise delivery of therapeutic agents, enhancing the stability and efficacy of the resulting compounds. Its application in PROTAC development and ADC formulation supports research into targeted protein degradation and innovative cancer therapies.

INX-P is an antibody-drug conjugate (ADC) linker designed for targeting glucocorticosteroids. It facilitates the delivery of cytotoxic agents specifically to cancer cells that express glucocorticoid receptors, enhancing therapeutic efficacy while minimizing systemic toxicity. This linker is particularly useful in research applications focusing on ADC development and targeted cancer therapies.

Gly-NH-CH2-Boc is a cleavable linker utilized in the synthesis of antibody-drug conjugates (ADCs). This reagent facilitates the attachment of cytotoxic agents to antibodies, allowing for targeted delivery of therapeutic compounds to cancer cells while minimizing off-target effects. Its application is critical in the development of novel ADCs for improved treatment efficacy in oncology research.

m-PEG7-Amine is a polyethylene glycol (PEG)-based linker designed for use in PROTAC (Proteolysis Targeting Chimeras) and antibody-drug conjugate (ADC) synthesis. This cleavable linker facilitates the targeted degradation of specific proteins, enhancing the efficacy of PROTACs. Its versatile application makes it an essential component in developing therapeutic modalities aimed at selective protein modulation and cancer treatment.

Boc-Val-Dil-Dap-OH is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates targeted drug delivery by enabling the release of cytotoxic agents selectively within tumor cells. Its unique structural features enhance the stability and efficacy of ADCs, making it suitable for research applications focused on cancer therapeutics and drug development.

Mal-PEG3-C1-NHS ester is a non-cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This triethylene glycol-based compound facilitates effective conjugation by providing a stable connection between the antibody and the therapeutic payload. Its application is crucial in enhancing the therapeutic efficacy and selectivity of ADCs in targeted cancer therapies and drug delivery systems.

Me-triacetyl-β-D-glucopyranuronate-Ph-ald-NO2 is a cleavable linker specifically designed for the construction of antibody-drug conjugates (ADCs). This compound facilitates the selective release of cytotoxic agents upon internalization by target cells, enhancing the therapeutic efficacy and reducing off-target effects. Its application in ADC development supports the advancement of targeted cancer therapies and other biopharmaceutical innovations.

Ald-CH2-PEG3-azide is a cleavable polyethylene glycol (PEG)-based linker designed for use in antibody-drug conjugates (ADCs) and proteolysis-targeting chimera (PROTAC) synthesis. This compound features an azide group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with alkyne-bearing molecules or DBCO/BCN groups. Its versatile chemistry facilitates the development of ADCs and PROTACs, making it invaluable for drug delivery and targeted therapeutic applications in chemical research.

Ald-Ph-amido-PEG4-C2-acid is a non-cleavable linker specifically designed for use in antibody-drug conjugates (ADCs). Its chemical structure facilitates stable attachment of drug molecules to antibodies, enhancing the therapeutic efficacy of ADCs. This linker is crucial for applications in targeted cancer therapy, allowing for the selective delivery of cytotoxic agents to tumors while minimizing off-target effects.